Table 2.
Characteristics of the study cohort.
| Crohn’s disease (n = 25) | Control (n = 26) |
P value | |
|---|---|---|---|
| Age (mean y, SD) (range) | 42.7 (9.9) (30-65) | 42.2 (9.0) (30-58) | .84 |
| Female sex | 17 (68%) | 21 (84%) | .32 |
| Race | .74 | ||
| Asian | 1 (4%) | 1(4%) | |
| Black | 2 (8%) | 5 (19%) | |
| White | 21 (84%) | 18 (69%) | |
| Preferred not to answer or missing | 1 (4%) | 2 (8%) | |
| Ethnicity | .32 | ||
| Hispanic | 0 (0%) | 3 (12%) | |
| Not Hispanic | 25 (96%) | 21 (81%) | |
| Prefer not to answer or missing | 1 (4%) | 2 (8%) | |
| Education | .13 | ||
| High school or less | 1 (4%) | 1 (4%) | |
| Some college | 3 (12%) | 5 (19%) | |
| 4-year college degree | 8 (32%) | 5 (19%) | |
| Graduate school | 9 (36%) | 15 (58%) | |
| Unreported | 4 (16%) | 0 (%) | |
| Phenotype | |||
| Inflammatory | 12 (48%) | N/A | N/A |
| Stricturing | 8 (32%) | N/A | N/A |
| Penetrating | 5 (20%) | N/A | N/A |
| Perianal fistula (ever) | 10 (40%) | N/A | N/A |
| Prior bowel resections (median, range) | 0 (0-3) | N/A | N/A |
| Current medications | |||
| 5ASA | 4 (16%) | N/A | N/A |
| Oral steroids | 3 (12%) | N/A | N/A |
| AZA/6MP/MTX | 8 (32%) | N/A | N/A |
| Anti-TNF | 11 (44%) | N/A | N/A |
| Vedolizumab | 2(8%) | N/A | N/A |
| Ustekinumab | 9 (36%) | N/A | N/A |
| JAKi | 0 (0%) | N/A | N/A |
| Short CDAI | 133.6 (73.6) (58-324) | N/A | N/A |
| sCDAI >150 | 10 (40%) | N/A | N/A |
| SES-CD | 1.6 (2.4) (0-9) | N/A | N/A |
| SES-CD >2 | 7 (28%) | N/A | N/A |
| hsCRP (mean, SD) | 3.8 (4.4) | N/A | N/A |
| PROMIS Fatigue | 52.1 (10.3) | 49.9 (8.5) | .41 |
| Promise Fatigue T ≥ 60 | 7 (28%) | 3 (11.5%) | .17 |
| MDFI Total | 53.5 (3.3) | 45.9 (3.1) | .11 |
| PROMIS Anxiety T-score | 50.51 (7.84) | 49.37(6.51) | .57 |
| PROMIS Depression T-score | 47.68 (7.70) | 48.11(7.53) | .84 |
| PROMIS Sleep Disturbance T-score | 54.12 (7.42) | 47.97(8.50) | .008 |
| Alcohol use (current use) | 7 (28%) | 7 (27%) | >.99 |
| Tobacco use (current use) | 0 (0%) | 4 (15%) | .11 |
| Recreational drugs (current use) | 2 (8%) | 0 (0%) | .24 |
| Narcotic use (current use)e | 1 (4%) | 0 (0%) | .49 |
| Anemiaa (n, %) | 6 (24%) | N/A | N/A |
| Vitamin B12 deficiencyb (n, %) | 0 (0%) | N/A | N/A |
| Iron deficiencyc (n, %) | 6 (24%) | N/A | N/A |
| Abnormal TSHd (n, %) | 3 (12%) | N/A | N/A |
aHemoglobin concentration <12 g/dL in females or <13.5 g/dL in males.
bVitamin B12 concentration <180 pg/mL.
cFerritin concentration <20 ng/mL.
dThyroid stimulating hormone <0.45 μlU/mL or >5.33 μlU/mL.
eOne patient was taking Tramadol after a recent surgery.